What do oligonucleotide and peptide therapeutics professionals expect to change in the next decade?
In March 2020, we surveyed a huge set of life sciences professionals representing every aspect of the global industry about the changes they expect to see over the next decade. With 432 responses, the results reveal unique insights into where those most central to the industry think the biggest opportunities and challenges lie in global pharma and biotech, and how they expect it to look in 2030.
The following report focuses exclusively on responses from professionals who specifically work with oligonucleotide and peptide therapeutics and small molecule drugs.